title: Early differential expression of oncostatin M in obstructive nephropathy.
abstract: Interstitial fibrosis plays a major role in progression of renal diseases. Oncostatin M (OSM) is a cytokine that regulates cell survival, differentiation, and proliferation. Renal tissue from patients with chronic obstructive nephropathy was examined for OSM expression. The elevated levels in diseased human kidneys suggested possible correlation between OSM level and kidney tissue fibrosis. Indeed, unilateral ureteral obstruction (UUO), a model of renal fibrosis, increased OSM and OSM receptor (OSM-R) expression in a time-dependent manner within hours following UUO. In vitro, OSM overexpression in tubular epithelial cells (TECs) resulted in epithelial-myofibroblast transdifferentiation. cDNA microarray technology identified up-regulated expression of immune modulators in obstructed compared with sham-operated kidneys. In vitro, OSM treatment up-regulated CC chemokine ligand CCL7, and CXC chemokine ligand (CXCL)-14 mRNA in kidney fibroblasts. In vivo, treatment of UUO mice with neutralizing anti-OSM antibody decreased renal chemokines expression. In conclusion, OSM is up-regulated in kidney tissue early after urinary obstruction. Therefore, OSM might play an important role in initiation of renal fibrogenesis, possibly by inducing myofibroblast transdifferentiation of TECs as well as leukocyte infiltration. This process may, in turn, contribute in part to progression of obstructive nephropathy and makes OSM a promising therapeutic target in renal fibrosis.
authors.affiliation: Department of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan. wbjeirami@khcc.jo
authors.forename: Wafa M
authors.initials: WM
authors.lastname: Elbjeirami
authors.forename: Luan D
authors.initials: LD
authors.lastname: Truong
authors.forename: Ahmad
authors.initials: A
authors.lastname: Tawil
authors.forename: Wansheng
authors.initials: W
authors.lastname: Wang
authors.forename: Sara
authors.initials: S
authors.lastname: Dawson
authors.forename: Hui Y
authors.initials: HY
authors.lastname: Lan
authors.forename: Ping
authors.initials: P
authors.lastname: Zhang
authors.forename: Gabriela E
authors.initials: GE
authors.lastname: Garcia
authors.forename: C
authors.initials: C
authors.lastname: Wayne Smith
mesh_terms: D000818:Animals; D019138:Antibodies, Blocking / Q000008:administration & dosage; D054338:Cell Transdifferentiation / Q000187:drug effects; D002478:Cells, Cultured; D018925:Chemokines / Q000096:biosynthesis* / Q000235:genetics; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D005355:Fibrosis; D020869:Gene Expression Profiling; D006801:Humans; D007684:Kidney Tubules / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D058628:Myofibroblasts / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D020411:Oligonucleotide Array Sequence Analysis; D053683:Oncostatin M / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D053677:Receptors, Oncostatin M / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D014517:Ureteral Obstruction / Q000235:genetics / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology
chemical_list: D019138:Antibodies, Blocking; D018925:Chemokines; D053677:Receptors, Oncostatin M; D053683:Oncostatin M